PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval

PF-07960613 is under clinical development by Pfizer and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to…